ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
Hodgie28
|
2.7K |
1.1M |
17 |
16/03/22 |
16/03/22 |
ASX - By Stock
|
2.7K
|
1.1M
|
17
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
Hodgie28
|
2.7K |
1.1M |
15 |
16/03/22 |
16/03/22 |
ASX - By Stock
|
2.7K
|
1.1M
|
15
|
|
Charts
|
IMU Biotech |
Re:
IMUGENE CHART. TA only
|
|
Hodgie28
|
33K |
16M |
17 |
14/02/22 |
14/02/22 |
Charts
|
33K
|
16M
|
17
|
|
ASX - By Stock
|
IMM |
Re:
Media
|
|
Hodgie28
|
382 |
194K |
7 |
11/02/22 |
11/02/22 |
ASX - By Stock
|
382
|
194K
|
7
|
|
ASX - By Stock
|
IMM |
Re:
Media
|
|
Hodgie28
|
382 |
194K |
15 |
28/01/22 |
28/01/22 |
ASX - By Stock
|
382
|
194K
|
15
|
|
ASX - By Stock
|
IMM |
Re:
Media
|
|
Hodgie28
|
382 |
194K |
15 |
27/01/22 |
27/01/22 |
ASX - By Stock
|
382
|
194K
|
15
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep Quarterly Activities Report and Appendix 4C
|
|
Hodgie28
|
21 |
8.1K |
14 |
25/01/22 |
25/01/22 |
ASX - By Stock
|
21
|
8.1K
|
14
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep Quarterly Activities Report and Appendix 4C
|
|
Hodgie28
|
21 |
8.1K |
7 |
25/01/22 |
25/01/22 |
ASX - By Stock
|
21
|
8.1K
|
7
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
Hodgie28
|
2.7K |
1.1M |
14 |
24/01/22 |
24/01/22 |
ASX - By Stock
|
2.7K
|
1.1M
|
14
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
Hodgie28
|
2.7K |
1.1M |
22 |
24/01/22 |
24/01/22 |
ASX - By Stock
|
2.7K
|
1.1M
|
22
|
|
ASX - By Stock
|
IMM |
Re:
Media
|
|
Hodgie28
|
382 |
194K |
14 |
10/01/22 |
10/01/22 |
ASX - By Stock
|
382
|
194K
|
14
|
|
ASX - By Stock
|
IMM |
Re:
Media
|
|
Hodgie28
|
382 |
194K |
30 |
17/12/21 |
17/12/21 |
ASX - By Stock
|
382
|
194K
|
30
|
|
ASX - By Stock
|
IMM |
Re:
a current prediction
|
|
Hodgie28
|
128 |
771K |
7 |
07/12/21 |
07/12/21 |
ASX - By Stock
|
128
|
771K
|
7
|
|
ASX - By Stock
|
IMM |
Re:
a current prediction
|
|
Hodgie28
|
128 |
771K |
0 |
07/12/21 |
07/12/21 |
ASX - By Stock
|
128
|
771K
|
0
|
|
ASX - By Stock
|
IMM |
Re:
a current prediction
|
|
Hodgie28
|
128 |
771K |
3 |
06/12/21 |
06/12/21 |
ASX - By Stock
|
128
|
771K
|
3
|
|
ASX - By Stock
|
IMM |
Re:
a current prediction
|
|
Hodgie28
|
128 |
771K |
1 |
06/12/21 |
06/12/21 |
ASX - By Stock
|
128
|
771K
|
1
|
|
ASX - By Stock
|
IMM |
Re:
a current prediction
|
|
Hodgie28
|
128 |
771K |
16 |
06/12/21 |
06/12/21 |
ASX - By Stock
|
128
|
771K
|
16
|
|
ASX - By Stock
|
IMM |
Re:
a current prediction
|
|
Hodgie28
|
128 |
771K |
1 |
06/12/21 |
06/12/21 |
ASX - By Stock
|
128
|
771K
|
1
|
|
ASX - By Stock
|
IMM |
Re:
a current prediction
|
|
Hodgie28
|
128 |
771K |
2 |
06/12/21 |
06/12/21 |
ASX - By Stock
|
128
|
771K
|
2
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Good safety reported from 1st five patients in INSIGHT-003
|
|
Hodgie28
|
42 |
15K |
12 |
03/12/21 |
03/12/21 |
ASX - By Stock
|
42
|
15K
|
12
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Good safety reported from 1st five patients in INSIGHT-003
|
|
Hodgie28
|
42 |
15K |
8 |
02/12/21 |
02/12/21 |
ASX - By Stock
|
42
|
15K
|
8
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Good safety reported from 1st five patients in INSIGHT-003
|
|
Hodgie28
|
42 |
15K |
8 |
02/12/21 |
02/12/21 |
ASX - By Stock
|
42
|
15K
|
8
|
|
ASX - By Stock
|
IMM |
Re:
a current prediction
|
|
Hodgie28
|
128 |
771K |
2 |
02/12/21 |
02/12/21 |
ASX - By Stock
|
128
|
771K
|
2
|
|
ASX - By Stock
|
IMM |
Re:
a current prediction
|
|
Hodgie28
|
128 |
771K |
7 |
02/12/21 |
02/12/21 |
ASX - By Stock
|
128
|
771K
|
7
|
|
ASX - By Stock
|
IMM |
Re:
a current prediction
|
|
Hodgie28
|
128 |
771K |
1 |
02/12/21 |
02/12/21 |
ASX - By Stock
|
128
|
771K
|
1
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Good safety reported from 1st five patients in INSIGHT-003
|
|
Hodgie28
|
42 |
15K |
7 |
02/12/21 |
02/12/21 |
ASX - By Stock
|
42
|
15K
|
7
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Change of Director's Interest Notice - Mr Voigt
|
|
Hodgie28
|
8 |
2.9K |
12 |
01/12/21 |
01/12/21 |
ASX - By Stock
|
8
|
2.9K
|
12
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Change of Director's Interest Notice - Mr Voigt
|
|
Hodgie28
|
8 |
2.9K |
12 |
01/12/21 |
01/12/21 |
ASX - By Stock
|
8
|
2.9K
|
12
|
|
ASX - By Stock
|
IMM |
Re:
IMM CHART / SP
|
|
Hodgie28
|
213 |
89K |
20 |
30/11/21 |
30/11/21 |
ASX - By Stock
|
213
|
89K
|
20
|
|
ASX - By Stock
|
IMM |
Re:
IMM CHART / SP
|
|
Hodgie28
|
213 |
89K |
14 |
30/11/21 |
30/11/21 |
ASX - By Stock
|
213
|
89K
|
14
|
|
ASX - By Stock
|
IMM |
Re:
IMM CHART / SP
|
|
Hodgie28
|
213 |
89K |
11 |
30/11/21 |
30/11/21 |
ASX - By Stock
|
213
|
89K
|
11
|
|
ASX - By Stock
|
IMM |
Re:
IMM CHART / SP
|
|
Hodgie28
|
213 |
89K |
5 |
30/11/21 |
30/11/21 |
ASX - By Stock
|
213
|
89K
|
5
|
|
ASX - By Stock
|
IMM |
Re:
IMM CHART / SP
|
|
Hodgie28
|
213 |
89K |
20 |
30/11/21 |
30/11/21 |
ASX - By Stock
|
213
|
89K
|
20
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Phase II TACTI-002 trial recruitment successfully completed
|
|
Hodgie28
|
88 |
34K |
10 |
25/11/21 |
25/11/21 |
ASX - By Stock
|
88
|
34K
|
10
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CLTX CAR T data shows regional control of tumour recurrence
|
|
Hodgie28
|
37 |
12K |
7 |
24/11/21 |
24/11/21 |
ASX - By Stock
|
37
|
12K
|
7
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Phase II TACTI-002 trial recruitment successfully completed
|
|
Hodgie28
|
88 |
34K |
15 |
24/11/21 |
24/11/21 |
ASX - By Stock
|
88
|
34K
|
15
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Phase II TACTI-002 trial recruitment successfully completed
|
|
Hodgie28
|
88 |
34K |
7 |
24/11/21 |
24/11/21 |
ASX - By Stock
|
88
|
34K
|
7
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Phase II TACTI-002 trial recruitment successfully completed
|
|
Hodgie28
|
88 |
34K |
9 |
24/11/21 |
24/11/21 |
ASX - By Stock
|
88
|
34K
|
9
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Phase II TACTI-002 trial recruitment successfully completed
|
|
Hodgie28
|
88 |
34K |
26 |
23/11/21 |
23/11/21 |
ASX - By Stock
|
88
|
34K
|
26
|
|
ASX - By Stock
|
IMM |
Re:
IMM CHART / SP
|
|
Hodgie28
|
213 |
89K |
4 |
23/11/21 |
23/11/21 |
ASX - By Stock
|
213
|
89K
|
4
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Phase II TACTI-002 trial recruitment successfully completed
|
|
Hodgie28
|
88 |
34K |
26 |
23/11/21 |
23/11/21 |
ASX - By Stock
|
88
|
34K
|
26
|
|
ASX - By Stock
|
IMM |
Re:
News: IMM Immutep Granted Chinese Patent For Eftilagimod Alpha A In Combination With A PD-1 Pathway...
|
|
Hodgie28
|
12 |
4.3K |
14 |
16/11/21 |
16/11/21 |
ASX - By Stock
|
12
|
4.3K
|
14
|
|
ASX - By Stock
|
IMM |
Re:
News: IMM Immutep Granted Chinese Patent For Eftilagimod Alpha A In Combination With A PD-1 Pathway...
|
|
Hodgie28
|
12 |
4.3K |
8 |
16/11/21 |
16/11/21 |
ASX - By Stock
|
12
|
4.3K
|
8
|
|
ASX - By Stock
|
IMU Biotech |
Re:
Imugene - Charts & Price Action (New thread)
|
|
Hodgie28
|
1.7K |
918K |
27 |
12/11/21 |
12/11/21 |
ASX - By Stock
|
1.7K
|
918K
|
27
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Final Phase IIb AIPAC clinical trial results for Efti in MBC
|
|
Hodgie28
|
108 |
44K |
14 |
11/11/21 |
11/11/21 |
ASX - By Stock
|
108
|
44K
|
14
|
|
ASX - By Stock
|
IMM |
Re:
News: IMM Immutep Reports Phase IIb Final AIPAC Study Results
|
|
Hodgie28
|
88 |
35K |
19 |
11/11/21 |
11/11/21 |
ASX - By Stock
|
88
|
35K
|
19
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Final Phase IIb AIPAC clinical trial results for Efti in MBC
|
|
Hodgie28
|
108 |
44K |
30 |
11/11/21 |
11/11/21 |
ASX - By Stock
|
108
|
44K
|
30
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Final Phase IIb AIPAC clinical trial results for Efti in MBC
|
|
Hodgie28
|
108 |
44K |
23 |
11/11/21 |
11/11/21 |
ASX - By Stock
|
108
|
44K
|
23
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Final Phase IIb AIPAC clinical trial results for Efti in MBC
|
|
Hodgie28
|
108 |
44K |
9 |
10/11/21 |
10/11/21 |
ASX - By Stock
|
108
|
44K
|
9
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Final Phase IIb AIPAC clinical trial results for Efti in MBC
|
|
Hodgie28
|
108 |
44K |
21 |
10/11/21 |
10/11/21 |
ASX - By Stock
|
108
|
44K
|
21
|
|